4basebio Plc – Appointment of CCO

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

4basebio PLC

(«4basebio» or the «Company»)

4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief
Commercial Officer

· Seasoned biotechnology commercial leader will drive global growth strategy
· Commercial team further bolstered by promotions of James Vang and Jennifer
Gelman to VP, Business Development and VP, Marketing, respectively

CAMBRIDGE, UK, 3 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic
DNA manufacturing and nucleic acids for next-generation therapeutics, announces
the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who
joined 4basebio in September 2025 as Vice President, Business Development, will
lead the Company’s global commercial strategy, business development initiatives,
and customer engagement as the Company scales its innovative synthetic DNA
platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine
markets.

Christine’s promotion follows the appointment of Dr Amy Walker as Chief
Executive Officer, replacing Dr Heikki Lanckriet. Christine will work closely
with Amy to execute 4basebio’s accelerated commercial growth strategy, focusing
on deepening penetration of the synthetic DNA market as customers seek
alternatives to plasmid DNA.

Christine brings more than 25 years of experience in the life sciences industry,
with a proven track record of building and scaling go-to-market capabilities in
the cell and gene therapy space. Prior to joining 4basebio, she served as Vice
President of Business Development at Emmes, where she led the buildout of the
North America commercial organisation to support growth in biopharma innovator
trials and later-phase studies. She established scalable, globally aligned
commercial processes and advanced Emmes’ strategic positioning within the
biopharma sector. Christine has also held senior global commercial leadership
roles at leading life sciences organisations including TriLink BioTechnologies
and Thermo Fisher Scientific, where she led the go-to-market launches for a
number of advanced therapy offerings, including Thermo Fisher Scientific’s viral
vector manufacturing expansion at its flagship Plainville, Massachusetts
facility.

Dr Amy Walker, Chief Executive Officer of 4basebio, commented: «4basebio is
moving into an accelerated commercial phase as the Company scales operations and
builds partnerships across RNA, cell and gene therapy and vaccine development.
Since joining 4basebio, Christine has demonstrated an ability to build strategic
relationships within the nucleic acid manufacturing space and a deep
understanding of customer needs in the advanced therapy sector. Her leadership
and experience will be instrumental as we work to establish 4basebio as the
partner of choice for companies developing next-generation therapeutics and
vaccines.»

Christine Wolosin, Chief Commercial Officer of 4basebio, commented: «4basebio’s
proprietary synthetic DNA platform addresses critical limitations of traditional
plasmid-based systems, offering biopharma partners key speed, purity and
scalability advantages. I have enjoyed working with the talented team at
4basebio to accelerate partnerships with innovators in gene therapy, mRNA
therapeutics, and next-generation vaccines. The market opportunity is
substantial, and we are uniquely positioned to capture it.»

To support the continued scaling of commercial operations, 4basebio has also
promoted James Vang to Vice President, Business Development and Jennifer Gelman
to Vice President, Marketing. James’ promotion recognises his significant
contributions to 4basebio’s commercial expansion since joining the Company,
while Jennifer’s reflects her leadership in establishing 4basebio’s market
presence and brand positioning.

For further enquiries, please contact:

4basebio PLC                +44 (0)12 2396 7943
Dr Amy Walker, CEO

Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes

Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks

RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes

ICR Healthcare (Media and Investor Relations) +44 (0)203 707 5700
Mary-Jane Elliott / Jessica Hodgson

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP
-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

For more information, visit 4basebio.com (https://www.4basebio.com/).

This information was brought to you by Cision http://news.cision.com